CymaBay Therapeutics Inc. (NASDAQ:CBAY) – Equities researchers at Leerink Swann cut their FY2017 EPS estimates for CymaBay Therapeutics in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of ($0.87) per share for the year, down from their prior forecast of ($0.85). Leerink Swann has a “Outperform” rating and a $12.00 price objective on the stock. Leerink Swann also issued estimates for CymaBay Therapeutics’ Q4 2017 earnings at ($0.17) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.86) EPS and FY2019 earnings at ($1.06) EPS.
Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. Oppenheimer Holdings, Inc. set a $15.00 target price on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Piper Jaffray Companies reissued a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Finally, SunTrust Banks, Inc. assumed coverage on shares of CymaBay Therapeutics in a research note on Friday, August 18th. They issued a “buy” rating and a $15.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. CymaBay Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.00.
TRADEMARK VIOLATION WARNING: This news story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.thestockobserver.com/2017/11/14/leerink-swann-equities-analysts-reduce-earnings-estimates-for-cymabay-therapeutics-inc-cbay.html.
Shares of CymaBay Therapeutics (CBAY) opened at $8.40 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics has a 12 month low of $1.46 and a 12 month high of $9.40.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same period last year, the firm earned ($0.25) EPS.
A number of hedge funds have recently added to or reduced their stakes in CBAY. Renaissance Technologies LLC raised its holdings in CymaBay Therapeutics by 97.6% in the 1st quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after acquiring an additional 114,549 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in CymaBay Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 140 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in CymaBay Therapeutics in the 2nd quarter valued at about $242,000. Vanguard Group Inc. raised its holdings in CymaBay Therapeutics by 20.7% in the 2nd quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock valued at $5,712,000 after acquiring an additional 170,126 shares during the last quarter. Finally, Ardsley Advisory Partners raised its holdings in CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors own 27.08% of the company’s stock.
In other CymaBay Therapeutics news, SVP Charles Mcwherter acquired 5,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was bought at an average price of $8.67 per share, for a total transaction of $43,350.00. Following the acquisition, the senior vice president now owns 10,300 shares in the company, valued at $89,301. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kurt Von Emster sold 211,124 shares of the stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $8.09, for a total transaction of $1,707,993.16. The disclosure for this sale can be found here. Insiders sold a total of 397,209 shares of company stock worth $3,267,417 over the last ninety days. 15.10% of the stock is currently owned by corporate insiders.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.